ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 1657 • ACR Convergence 2023

    Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution

    Gabrielle Rabadam1, Camilla Wibrand2, Emily Flynn1, George Hartoularos1, Yang Sun1, Susan Kim3, Chun Jimmie Ye1, Zev Gartner1, Marina Sirota4 and Jessica Neely1, 1University of California San Francisco, San Francisco, CA, 2Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, 3UCSF Benioff Children's Hospital, San Francisco, CA, 4Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA

    Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare multisystem autoimmune condition that involves complex immune responses in both innate and adaptive compartments. Currently, we have a…
  • Abstract Number: 2579 • ACR Convergence 2023

    Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies

    Emma Austenfeld1, Sara Sabbagh1, Melodee Liegl1, Ke Yan1, Julie Fuller2, Kelly Rouster-Stevens3, Lisa Rider4 and Adam Schiffenbauer4, 1Medical College of Wisconsin, Wauwatosa, WI, 2UT Southwestern and Scottish Rite for Children, Dallas, TX, 3Emory University/Children's Healthcare of Atlanta, Norcross, GA, 4NIEHS, NIH, Bethesda, MD

    Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
  • Abstract Number: 0085 • ACR Convergence 2023

    Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis

    DeAnna Diaz1, Muhammad Bashir1, Rohan Dhiman2, Avital Baniel1, Julianne Kleitsch1, Rachita Pandya1, Meena Sharma1, Thomas Vazquez1, Ming-Lin Liu2, Mariko Momohara2 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. The activation of CB2R has been shown to reduce several,…
  • Abstract Number: 1163 • ACR Convergence 2023

    Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort

    Sai Koyoda1, Dawn Wahezi2, Xianhong Xie3, Anand Kumthekar4, Clement Tagoe3 and Bibi Ayesha5, 1Essen Medical Center, Rahway, NJ, 2Children's Hospital at Montefiore, New Rochelle, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 5Montefiore Medical Center, Bronx, NY

    Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
  • Abstract Number: 1709 • ACR Convergence 2023

    Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction

    Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
  • Abstract Number: 0126 • ACR Convergence 2023

    Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population

    Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
  • Abstract Number: 1164 • ACR Convergence 2023

    Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study

    Carina Soto-Fajardo1, Sinthia Solorzano Flores1, Abish Angeles-Acuña1, Fabian Carranza Enriquez1, Rosa-Elena Escobar-Cedillo2, Saul Renan-Leon2, Karina Arias Callejas3, Alejandra Enriquez-Luna2, Graciliano Ramon-Diaz2 and Carlos Pineda2, 1Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, 2Instituto Nacional de Rehabilitacion, Mexico City, Mexico, 3Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico

    Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…
  • Abstract Number: 1814 • ACR Convergence 2023

    Silica and Other Exposures from Jobs and Hobbies Are Associated with Myositis Phenotype in a National Myositis Registry

    Christine Parks1, Jesse Wilkerson2, Payam Noroozi Farhad3, Nastaran Bayat4, Adam Schiffenbauer5, Hermine Brunner6, Robert Goldberg7, Frederick Miller8 and Lisa Rider5, 1Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 2NIEHS/NIH, Durham, NC, 3Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 4Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, 5NIEHS, NIH, Bethesda, MD, 6Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 7Myositis Foundation, Alexandria, VA, 8NIH, NIEHS, Chapel Hill, NC

    Background/Purpose: Growing evidence suggests that environmental factors may contribute to disease phenotype among patients diagnosed with the idiopathic inflammatory myopathies (IIM), dermatomyositis (DM), polymyositis (PM),…
  • Abstract Number: 0285 • ACR Convergence 2023

    Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis

    Lisa Christopher-Stine1, Julie Paik1, Brendan M. Johnson2, Taryn Smith2, Jolie Feldman2 and Paul N. Mudd Jr.2, 1Johns Hopkins University, Baltimore, MD, 2Priovant Therapeutics, Durham, NC

    Background/Purpose: Dermatomyositis (DM) is a rare, debilitating, idiopathic inflammatory myopathy characterized by painful, itchy skin rash and proximal muscle weakness that can significantly impact daily…
  • Abstract Number: 1165 • ACR Convergence 2023

    Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America

    Jenice Cheah1, Sangmee Bae2, Tiffany De Leon2, Yuna Lee1 and Christina Charles-Schoeman3, 1University of California Los Angeles, Los Angeles, CA, 2UCLA Rheumatology, Los Angeles, CA, 3UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
  • Abstract Number: 1946 • ACR Convergence 2023

    Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis

    Rohit Aggarwal1, Namita Goyal2, Diana Lam3, Allen Ng3, Richard Leff4, Kathryn Ray3, Eunmi Park3 and Noreen Henig3, 1University of Pittsburgh, Pittsburgh, PA, 2UCI Health, Orange, CA, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Chadds Ford, PA

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases characterized by muscle inflammation and weakness. In a collagen-induced myositis mouse model, immunoproteasome inhibition has…
  • Abstract Number: 0289 • ACR Convergence 2023

    Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity

    Sangmee Bae1, Ani Shahbazian1, Jennifer Wang2, Tiffany De Leon1, Yuna Lee1, srinivasa Reddy3 and Christina Charles-Schoeman4, 1UCLA Rheumatology, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, 4UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Damage to the vascular endothelium is implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM) and its associated interstitial lung disease (ILD), with microvascular…
  • Abstract Number: 1167 • ACR Convergence 2023

    Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)

    Yoshinobu Koyama1, Yoshiharu Sato2, Yu Nakai3 and Moe Tokunaga(Sakamoto)3, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan, 3Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan

    Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
  • Abstract Number: 1949 • ACR Convergence 2023

    Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis

    Noriko Sasaki, Toshiki Ohisa, Akira Ishii, Mai Sugiyama, Yuichiro Ota, Chiho Yamada and Shinji Sato, Tokai university School of Medicine, Isehara, Japan

    Background/Purpose: Autoantibodies to Melanoma Differentiation-Associated Gene 5 (MDA5) are found specifically in patients with dermatomyositis (DM). Their presence is closely associated with rapidly progressive interstitial…
  • Abstract Number: 0297 • ACR Convergence 2023

    Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series

    Eaman Alhassan1, Belina Yi2, Jack Rodman1 and Leanna Wise3, 1University of Southern California, Los Angeles, CA, 2Children's Hospital Los Angeles, Los Angeles, CA, 3LAC+USC/Keck Medicine of USC, Pasadena, CA

    Background/Purpose: There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis patients in a primarily U.S.…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology